Key facts
- It has raised $69.1M; the latest was Later Stage VC ($50.0M) in Aug 2024.
- Notable investors include Scottish Enterprise, The Scottish National Investment Bank, Alba Equity, Apollo Informal Investment, Eos Advisory — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Cumulus Oncology
- ·The full record, as it builds
Funding rounds
No funding rounds for Cumulus Oncology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cumulus Oncology
Developer of novel therapies designed for treating cancers. The company's lead candidate is an oral, selective, and preclinical Chk1 kinase inhibitor that helps in the activation of DNA repair, enabling the medical community to optimize the efficacy and outcomes for cancer patients.
- Sector
- Healthcare
- HQ
- Edinburgh, United Kingdom
- Founded
- 2017
- Employees
- 13
- Website
- cumulusoncology.com/
- Ownership
- Privately Held (backing)
Cumulus Oncology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cumulus Oncology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cumulus Oncology in its N-PORT filings yet. We sweep new filings monthly.